Riociguat in Scleroderma Associated Digital Ulcers
Status:
Completed
Trial end date:
2018-07-24
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to provide preliminary data on the efficacy (digital
ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to
placebo in patients with scleroderma-associated digital ulcers